» Articles » PMID: 38618959

Complement C3 and Marginal Zone B Cells Promote IgG-mediated Enhancement of RBC Alloimmunization in Mice

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2024 Apr 15
PMID 38618959
Authors
Affiliations
Soon will be listed here.
Abstract

Administration of anti-RhD immunoglobulin (Ig) to decrease maternal alloimmunization (antibody-mediated immune suppression [AMIS]) was a landmark clinical development. However, IgG has potent immune-stimulatory effects in other settings (antibody-mediated immune enhancement [AMIE]). The dominant thinking has been that IgG causes AMIS for antigens on RBCs but AMIE for soluble antigens. However, we have recently reported that IgG against RBC antigens can cause either AMIS or AMIE as a function of an IgG subclass. Recent advances in mechanistic understanding have demonstrated that RBC alloimmunization requires the IFN-α/-β receptor (IFNAR) and is inhibited by the complement C3 protein. Here, we demonstrate the opposite for AMIE of an RBC alloantigen (IFNAR is not required and C3 enhances). RBC clearance, C3 deposition, and antigen modulation all preceded AMIE, and both CD4+ T cells and marginal zone B cells were required. We detected no significant increase in antigen-specific germinal center B cells, consistent with other studies of RBC alloimmunization that show extrafollicular-like responses. To the best of our knowledge, these findings provide the first evidence of an RBC alloimmunization pathway which is IFNAR independent and C3 dependent, thus further advancing our understanding of RBCs as an immunogen and AMIE as a phenomenon.

Citing Articles

ABO blood groups and galectins: Implications in transfusion medicine and innate immunity.

Arthur C, Hollenhorst M, Wu S, Jajosky R, Nakahara H, Jan H Semin Immunol. 2024; 74-75:101892.

PMID: 39405833 PMC: 11808837. DOI: 10.1016/j.smim.2024.101892.


Harnessing the potential of red blood cells in immunotherapy.

Jajosky R, Zerra P, Chonat S, Stowell S, Arthur C Hum Immunol. 2024; 85(6):111084.

PMID: 39255557 PMC: 11808826. DOI: 10.1016/j.humimm.2024.111084.

References
1.
Mener A, Patel S, Arthur C, Chonat S, Wieland A, Santhanakrishnan M . Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses. JCI Insight. 2018; 3(22). PMC: 6302935. DOI: 10.1172/jci.insight.121631. View

2.
Hendrickson J, Saakadze N, Cadwell C, Upton J, Mocarski E, Hillyer C . The spleen plays a central role in primary humoral alloimmunization to transfused mHEL red blood cells. Transfusion. 2009; 49(8):1678-84. PMC: 3568957. DOI: 10.1111/j.1537-2995.2009.02200.x. View

3.
Calabro S, Gallman A, Gowthaman U, Liu D, Chen P, Liu J . Bridging channel dendritic cells induce immunity to transfused red blood cells. J Exp Med. 2016; 213(6):887-96. PMC: 4886363. DOI: 10.1084/jem.20151720. View

4.
Escamilla-Rivera V, Liu J, Gibb D, Santhanakrishnan M, Liu D, Forsmo J . Poly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice. Blood. 2020; 135(22):1983-1993. PMC: 7256361. DOI: 10.1182/blood.2020005018. View

5.
Zhang X, Luo M, Dastagir S, Nixon M, Khamhoung A, Schmidt A . Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic. Nat Commun. 2021; 12(1):2637. PMC: 8113241. DOI: 10.1038/s41467-021-22898-3. View